Data From Proof-of-Concept Clinical Trial of ALD403, a Monoclonal Antibody Against CGRP for the Prevention of Migraine, to be Presented at 56th Annual Scientific Meeting of the American Headache Society
June 26, 2014 08:00 ET
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., June 26, 2014 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. ("Alder") (Nasdaq:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics for the...
Alder BioPharmaceuticals Reports First Quarter 2014 Financial Results
June 18, 2014 17:35 ET
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., June 18, 2014 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. ("Alder") (Nasdaq:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics for the...
Alder BioPharmaceuticals to Present at Two Conferences in June
June 11, 2014 08:00 ET
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., June 11, 2014 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc., ("Alder") (Nasdaq:ALDR), a clinical-stage biopharmaceutical company developing therapeutic antibodies for the...
Data From Proof-of-Concept Clinical Trial of ALD403, a Monoclonal Antibody Against CGRP for the Prevention of Migraine, to be Presented at American Academy of Neurology Meeting
April 23, 2014 08:00 ET
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., April 23, 2014 (GLOBE NEWSWIRE) -- Alder Biopharmaceuticals Inc. today announced that Dr. Peter J. Goadsby, M.D., Ph.D., director, NIHR-Wellcome Trust Clinical Research Facility,...